📰 Beigene News
Page 14 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
November 22, 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented
November 17, 2022
BRUKINSA is the only Bruton's Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy
November 15, 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important
November 10, 2022
BRUKINSA now approved in Brazil for three indications BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology, today announced BRUKINSA (zanubrutinib) has been approved in Brazil
November 9, 2022
Recorded product revenue of $349.5 million for the third quarter, representing an 82% increase from $192.5 million in the prior-year period BRUKINSA product revenue totaled $155.5 million, increasing
November 4, 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences: The 6th Annual Cowen IO
November 2, 2022
BRUKINSA is the first and only Bruton's Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma approved in the European Union BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology
October 26, 2022
BRUKINSA received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology
October 14, 2022
14.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee ... Seite 1
October 12, 2022
12.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA ... Seite 1